Pearl-clutchers Demand FDA Do Something, Anything, About CBD

Name: Pearl-clutchers Demand FDA Do Something, Anything, About CBD
Brand: The Richard Rose Report
SKU: 60844
Availability: InStock

Pearl-clutchers Demand FDA Do Something, Anything, About CBD, by Richard Rose. 21 pages.

Copyright 1994-2024 Richard Rose, all rights reserved. Any views expressed herein are the personal opinion of Richard Rose. This is a noncommercial public service. There are no warranties whatsoever as to the legality, suitability, ownership, purpose, or accuracy of this information. I am not a doctor or a lawyer. If you have medical questions, please seek a medical professional. If you have legal questions, please seek a legal professional. Information found here is not intended to diagnose, cure, treat, or prevent any disease. These statements and subsequent links found here have not been evaluated by the U.S. Food and Drug Administration (FDA). Hemp is not subject to international drug controls and is grown legally around the world. The information posted here is for educational purposes only and is not to be considered legal or medical advice, and is not intended to replace consultation with a qualified legal or medical professional. This website uses cookies. By continuing to use this service, you agree to their use. This is provided on an “as is,” “as available” basis without warranties of any kind, express or implied. The user assumes all responsibility and risk for the use of this website. Links are provided only as an informational resource, and it should not be implied that we own, recommend, endorse or approve of any of the content at the linked sites, nor are we responsible for their content. Unless otherwise stated, nobody pays us nuttin’ to post content, and we have no sponsors unlike NASCAR. By providing your email address to us you agree to be on the free The Richard Rose Report… This Week mailing list; you may unsubscribe at any time. There is no charge. To learn more about how we collect, keep, and process your private information in compliance with GDPR, please view our privacy policy via a link at the bottom of this page. Void where prohibited. Specifications subject to change without notice. If you don’t agree with the above please leave immediately. All patents, service marks, trademarks, and copyrights are the property of their respective owners. To the best of my knowledge, all Articles, Downloads, and Posts authored by RR are absolutely not written with any type of AI, just a human brain. Grammarly and autocorrect might be used to make minor edits. Posts authored under CannaSearch Daily are written by the original external poster, and no claim is made for those. It’s obvious that GPT language models will be deployed everywhere, but their accuracy is still low so I avoid them for now. Plus writers write.

Potency analysis of twelve cannabinoids in industrial hemp via ultrahigh-performance liquid chromatography-tandem mass spectrometry July 22, 2024
CONCLUSIONS: This study established a UHPLC-MS/MS method for the simultaneous and rapid quantitative determination of twelve cannabinoids in industrial hemp flowers and leaves in 11 min. The method was used to analyze 43 industrial hemp flower and leaf samples, with the data being statistically analyzed. Based on the statistical analysis of the cannabinoids, hemp from […]
Oral pre- and early postnatal cannabis exposure disinhibits ventral tegmental area dopamine neuron activity but does not influence cocaine preference in offspring in mice July 22, 2024
Cannabis consumption has increased from 1.5% to 2.5% in Canada between 2012 and 2019. Clinical studies have indicated effects of prenatal cannabis exposure on birth weight, substance use, and neurodevelopmental disorders, but are confounded by several difficult to control variables. Animal models allow for examination of the mechanism of cannabis-induced changes in neurodevelopment and behavior, […]
Preventing new substance use behaviors in youth: evaluation of a two-year comprehensive program July 22, 2024
INTRODUCTION: The Avenir Santé Association implemented a comprehensive prevention program targeting the consumption of the emerging psychoactive substances ecstasy (MDMA), cannabidiol (CBD), and nitrous oxide (N(2)O).
Elemental Profiling of Common Anti-diabetic Medicinal Plants of Swat and Peshawar Districts of Khyber Pakhtunkhwa (KPK) Province of Pakistan: An Investigation Using PIXE and ICP-OES July 22, 2024
The use of medicinal plants is integral to addressing liver, heart, lung, and other metabolic issues. These plants are rich in vitamins, minerals, flavonoids, and alkaloids, which collectively help in lowering intestinal glucose absorption and increasing insulin secretion by pancreatic tissues. Elemental analysis, encompassing major, minor, and trace elements, was performed on various parts (leaves, […]
Modeling the liquid-liquid chromatography separation of cannabinoids from hemp extracts July 20, 2024
The separation of cannabinoids from hemp materials is nowadays one of the most promising industrial applications of liquid-liquid chromatography (LLC). Despite various experimental research efforts to purify cannabinoids, there are currently few works on process modeling. Thus, this study aimed to explore a straightforward approach to model the LLC separation of cannabinoids from two hemp […]
Association between cannabis use and nicotine use persistence among adolescents July 20, 2024
CONCLUSIONS: Adolescents who use cannabis may be at elevated risk for persistent nicotine use.
The anxiolytic effects of cannabinoids: A comprehensive review July 20, 2024
Cannabinoids, notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), have emerged as promising candidates for anxiety disorder treatment, supported by both preclinical and clinical evidence. CBD exhibits notable anxiolytic effects with a favourable safety profile, though concerns regarding mild side effects and drug interactions remain. Conversely, THC, the primary psychoactive compound, presents a range of side effects, […]
Cannabidiol effects on fear processing and implications for PTSD: Evidence from rodent and human studies July 19, 2024
Cannabidiol (CBD) modulates aversive memory and its extinction, with potential implications for treating anxiety- and stress-related disorders. Here, we summarize and discuss scientific evidence showing that CBD administered after the acquisition (consolidation) and retrieval (reconsolidation) of fear memory attenuates it persistently in rats and mice. CBD also reduces fear expression and enhances fear extinction. These […]
Therapeutic potential of cannabidiol in depression July 19, 2024
Major depressive disorder (MDD) is a widespread and debilitating condition affecting a significant portion of the global population. Traditional treatment for MDD has primarily involved drugs that increase brain monoamines by inhibiting their uptake or metabolism, which is the basis for the monoaminergic hypothesis of depression. However, these treatments are only partially effective, with many […]
Cannabidiol and pain July 19, 2024
Chronic pain presents significant personal, psychological, and socioeconomic hurdles, impacting over 30% of adults worldwide and substantially contributing to disability. Unfortunately, current pharmacotherapy often proves inadequate, leaving fewer than 70% of patients with relief. This shortfall has sparked a drive to seek alternative treatments offering superior safety and efficacy profiles. Cannabinoid-based pharmaceuticals, notably cannabidiol (CBD), […]
Assessment of the nociceptive response to the use of cannabidiol alone and in combination with meloxicam through infrared pupillometry in female dogs undergoing elective ovariohysterectomy July 19, 2024
The negative effects of pain are a constant concern in the surgical management of animals, leading to the search for new drugs or more effective analgesic protocols to control this negative emotion. This study aimed to evaluate the nociceptive response of cannabidiol (CBD) alone and in combination with meloxicam using infrared pupillometry in female dogs […]
Historical perspective on the therapeutic potential of cannabidiol July 19, 2024
Cannabidiol (CBD) is one of over 200 cannabinoids present in the Cannabis plant. Unlike the plant's primary cannabinoid, delta-9-tetrahydrocannabinol (THC), CBD does not produce psychotomimetic effects nor induce dependence. Initially considered an inactive cannabinoid, interest in its pharmacological properties and therapeutic potential has grown exponentially over the last 20 years. Currently employed as a medication […]
Cannabidiol and Alzheimer's disease July 19, 2024
Alzheimer's disease (AD) stands as the most prevalent form of neuropsychiatric disorder among the elderly population, impacting a minimum of 50 million individuals worldwide. Current pharmacological treatments rely on the prescribing cholinesterase inhibitors and memantine. However,recently anecdotal findings based on low-quality real-world data had prompted physicians, patients, and their relatives to consider the use of […]
Cannabidiol in experimental cerebral ischemia July 19, 2024
The absence of blood flow in cerebral ischemic conditions triggers a multitude of intricate pathophysiological mechanisms, including excitotoxicity, oxidative stress, neuroinflammation, disruption of the blood-brain barrier and white matter disarrangement. Despite numerous experimental studies conducted in preclinical settings, existing treatments for cerebral ischemia (CI), such as mechanical and pharmacological therapies, remain constrained and often entail […]
Therapeutic potential of CBD in Autism Spectrum Disorder July 19, 2024
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent deficits in social communication and interaction, as well as restricted and repetitive patterns of behavior. Despite extensive research, effective pharmacological interventions for ASD remain limited. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has potential therapeutic effects on several neurological and psychiatric […]
Cannabidiol and epilepsy July 19, 2024
Cannabidiol (CBD) has been investigated as a pharmacological approach for treating a myriad of neurological and psychiatric disorders, the most successful of them being its use as an antiseizure drug (ASD). Indeed, CBD has reached the clinics for the treatment of certain epileptic syndromes. This chapter aims to overview the pharmacology of CBD and its […]
A journey through cannabidiol in Parkinson's disease July 19, 2024
Parkinson's disease is a chronic neurodegenerative disorder with no known cure characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Non-motor symptoms like cognitive impairment, mood disturbances, and sleep disorders often accompany the disease. Pharmacological treatments for these symptoms are limited and frequently induce significant adverse reactions, underscoring the […]
Cannabidiol: Pharmacodynamics and pharmacokinetic in the context of neuropsychiatric disorders July 19, 2024
In this chapter we explored the growing interest in cannabinoids, particularly cannabidiol (CBD), over the last two decades due to their potential therapeutic applications in neurodegenerative and psychiatric disorders. CBD, a major non-psychotomimetic compound derived from Cannabis sativa, is highlighted as a safer alternative to other cannabinoids like Δ9-tetrahydrocannabinol (THC). Clinical trials have been investigating […]
Cannabidiol and addiction July 19, 2024
Cannabidiol (CBD) has been investigated for several therapeutic applications, having reached the clinics for the treatment of certain types of epilepsies. This chapter reviews the potential of CBD for the treatment of substance use disorders (SUD). We will present a brief introduction on SUD and current treatments. In the second part, preclinical and clinical studies […]
Cannabinoid Content and Label Accuracy of Various Hemp-Derived Haircare, Cosmetic, and Edible Products Available at Retail Stores and Online in the United States July 19, 2024
Aim: To evaluate the label accuracy and content of various hemp-derived cannabidiol (CBD) products (cannabinoid products with ≤0.3% Δ⁹-tetrahydrocannabinol [THC]), as well as evaluate advertised claims on product labels. Methods: Hemp haircare, cosmetics, and food/drink products that were advertised to contain CBD were purchased from retail stores in the Baltimore, Maryland area (purchased in July […]